ChromaDex Shares Surge After Beating Q4 Earnings Expectations
Generated by AI AgentMarcus Lee
Wednesday, Mar 5, 2025 12:41 pm ET1min read
CDXC--
ChromaDex Corp. (CDXC) shares rose 56% to $8.73 on Wednesday after the company reported fourth-quarter earnings that surpassed analyst expectations. The bioscience company, which focuses on nicotinamide adenine dinucleotide (NAD+) research, posted quarterly earnings of $7.2 million, or nine cents per share, compared to earnings of $114,000, or zero cents per share, in the same quarter last year. Analysts polled by FactSetFDS-- were expecting earnings of $1.7 million, or two cents per share.
Sales for the quarter were $29.1 million, compared to last year's $21.2 million and the $26.8 million analysts were expecting. The company's lead product, Tru Niagen, saw sales rise 29% from a year earlier, primarily from e-commerce. ChromaDexCDXC-- is forecasting an 18% increase in sales for 2025.
FDS--
NAD--
ChromaDex Corp. (CDXC) shares rose 56% to $8.73 on Wednesday after the company reported fourth-quarter earnings that surpassed analyst expectations. The bioscience company, which focuses on nicotinamide adenine dinucleotide (NAD+) research, posted quarterly earnings of $7.2 million, or nine cents per share, compared to earnings of $114,000, or zero cents per share, in the same quarter last year. Analysts polled by FactSetFDS-- were expecting earnings of $1.7 million, or two cents per share.
Sales for the quarter were $29.1 million, compared to last year's $21.2 million and the $26.8 million analysts were expecting. The company's lead product, Tru Niagen, saw sales rise 29% from a year earlier, primarily from e-commerce. ChromaDexCDXC-- is forecasting an 18% increase in sales for 2025.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet